Gilead Sciences Inc (GILD)
Gilead Sciences is a biopharmaceutical company, focusing on medicines to prevent and treat diseases, including HIV, viral hepatitis and cancer. Co.'s products include: Biktarvy®, which is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients; Veklury® (remdesivir), an injection for intravenous use, which is a nucleotide analog RNA polymerase inhibitor indicated for certain patients for the treatment of COVID-19 requiring hospitalization; and Epclusa®, which is an oral formulation of a once-daily single tablet regimen of sofosbuvir and velpatasvir for the treatment of chronic hepatitis C virus (HCV) infection in adults and certain pediatric patients.
Gilead Sciences SEC Filing Email Alerts Service
Company Name: |
Gilead Sciences Inc |
Stock buyback: |
GILD buyback |
Website: |
www.gilead.com |
Sector: |
Biotechnology |
Number of ETFs Holding GILD: |
133 |
Total Market Value Held by ETFs: |
$13.22B |
Total Market Capitalization: |
$83.85B |
% of Market Cap. Held by ETFs: |
15.76% |
|
|
April 19, 2024 3:23 AM Eastern
Buy (2.83 out of 4)
100th percentile
|
|